Home › Acute Myeloid Leukemia › NCT06580106

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years of age at the time of consent
* Confirmed diagnosis of AML
* Planned initial treatment with azacitidine and venetoclax
* Ability to read and understand the English and/or Spanish language
* As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study

Exclusion Criteria:

* None

About the study

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

What is being tested

• Biospecimen samples (other)

Sponsor: Wake Forest University Health Sciences · Participants: 50 · Started: Apr 9, 2025

Contact the study team

• Courtney Schepel · Phone: (980) 292-0817

Official record on ClinicalTrials.gov — NCT06580106

Locations in the U.S.

Conditions

• Acute Myeloid Leukemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.